From clinical trials to clinical practice: therapeutic cancer vaccines for the treatment of prostate cancer

被引：0
作者：
Madan, Ravi A. [1 ,2 ]
Aragon-Ching, Jeanny B. [2 ]
Gulley, James L. [1 ,2 ]
Dahut, William L. [2 ]
机构：
[1] NCI, Lab Tumor Immunol & Biol, Ctr Canc Res, NIH, Bethesda, MD 20912 USA
[2] NCI, Med Oncol Branch, Ctr Canc Res, NIH, Bethesda, MD 20912 USA
来源：
EXPERT REVIEW OF VACCINES | 2011年 / 10卷 / 06期
关键词：
castration-resistant; metastatic; prostate cancer; therapeutic cancer vaccine; treatment; REGULATORY T-CELLS; ANDROGEN-DEPRIVATION THERAPY; ABIRATERONE ACETATE; SIPULEUCEL-T; COMBINATION THERAPY; IMMUNE-RESPONSES; DENDRITIC CELLS; PLUS PREDNISONE; CUTTING EDGE; LUNG-CANCER;
D O I：
10.1586/ERV.11.70
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Therapeutic options for patients with metastatic castration-resistant prostate cancer are increasing, spurring an urgent need to better understand which treatments are best for individual patients. The recent approval of a first-in-class agent, sipuleucel-T, has intensified this need. This therapeutic cancer vaccine has demonstrated a survival advantage in two Phase Ill trials, but does not alter progression in the short term. Therefore, a new therapeutic approach for patients with metastatic castration-resistant prostate cancer is taking shape, based on broader understanding of available therapies. This new clinical approach seeks to maximize patient benefit from treatment, minimize associated toxicities, and may have far-reaching implications for other therapeutic cancer vaccines currently in clinical development.
引用
收藏
页码：743 / 753
页数：11
相关论文
共 50 条
[41]   Clinical perspectives from ongoing trials in oligometastatic or oligorecurrent prostate cancer: an analysis of clinical trials registries [J].
De Bruycker, Aurelie ;
Tran, Phuoc T. ;
Achtman, Ariel H. ;
Ost, Piet .
WORLD JOURNAL OF UROLOGY, 2021, 39 (02) :317-326
[42]   Prostate cancer vaccines: the long road to clinical application [J].
Constantin N. Baxevanis ;
Michael Papamichail ;
Sonia A. Perez .
Cancer Immunology, Immunotherapy, 2015, 64 :401-408
[43]   DNA vaccines for the treatment of prostate cancer [J].
Alam, Sheeba ;
McNeel, Douglas G. .
EXPERT REVIEW OF VACCINES, 2010, 9 (07) :731-745
[44]   Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with prostate cancer [J].
Kanesvaran, R. ;
Castro, E. ;
Wong, A. ;
Fizazi, K. ;
Chua, M. L. K. ;
Zhu, Y. ;
Malhotra, H. ;
Miura, Y. ;
Lee, J. L. ;
Chong, F. L. T. ;
Pu, Y-S ;
Yen, C-C ;
Saad, M. ;
Lee, H. J. ;
Kitamura, H. ;
Prabhash, K. ;
Zou, Q. ;
Curigliano, G. ;
Poon, E. ;
Choo, S. P. ;
Peters, S. ;
Lim, E. ;
Yoshino, T. ;
Pentheroudakis, G. .
ESMO OPEN, 2022, 7 (04)
[45]   Clinical Evaluation of TRICOM Vector Therapeutic Cancer Vaccines [J].
Madan, Ravi A. ;
Bilusic, Marijo ;
Heery, Christopher ;
Schlom, Jeffrey ;
Gulley, James L. .
SEMINARS IN ONCOLOGY, 2012, 39 (03) :296-304
[46]   Prostate cancer vaccines in combination with additional treatment modalities [J].
Uhlman, Matthew A. ;
Bing, Megan T. ;
Lubaroff, David M. .
IMMUNOLOGIC RESEARCH, 2014, 59 (1-3) :236-242
[47]   Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J].
Parker, C. ;
Castro, E. ;
Fizazi, K. ;
Heidenreich, A. ;
Ost, P. ;
Procopio, G. ;
Tombal, B. ;
Gillessen, S. .
ANNALS OF ONCOLOGY, 2020, 31 (09) :1119-1134
[48]   Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upaEuro [J].
Parker, C. ;
Gillessen, S. ;
Heidenreich, A. ;
Horwich, A. .
ANNALS OF ONCOLOGY, 2015, 26 :V69-V77
[49]   Prevention is Better Than Cure: The Case for Clinical Trials of Therapeutic Cancer Vaccines in the Prophylactic Setting [J].
Gray, Andrew ;
Yan, Lisa ;
Kast, W. Martin .
MOLECULAR INTERVENTIONS, 2010, 10 (04) :197-203
[50]   Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials [J].
Templeton, A. J. ;
Vera-Badillo, F. E. ;
Wang, L. ;
Attalla, M. ;
De Gouveia, P. ;
Leibowitz-Amit, R. ;
Knox, J. J. ;
Moore, M. ;
Sridhar, S. S. ;
Joshua, A. M. ;
Pond, G. R. ;
Amir, E. ;
Tannock, I. F. .
ANNALS OF ONCOLOGY, 2013, 24 (12) :2972-2977
12345